1. Home
  2. NERV vs NKTX Comparison

NERV vs NKTX Comparison

Compare NERV & NKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Minerva Neurosciences Inc

NERV

Minerva Neurosciences Inc

HOLD

Current Price

$6.33

Market Cap

301.6M

Sector

Health Care

ML Signal

HOLD

Logo Nkarta Inc.

NKTX

Nkarta Inc.

HOLD

Current Price

$2.69

Market Cap

247.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NERV
NKTX
Founded
2007
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
301.6M
247.4M
IPO Year
2014
2020

Fundamental Metrics

Financial Performance
Metric
NERV
NKTX
Price
$6.33
$2.69
Analyst Decision
Buy
Strong Buy
Analyst Count
2
4
Target Price
$10.50
$11.33
AVG Volume (30 Days)
192.7K
948.3K
Earning Date
05-01-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
11.88
EPS
N/A
N/A
Revenue
$41,175,600.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.30
$1.63
52 Week High
$12.46
$3.65

Technical Indicators

Market Signals
Indicator
NERV
NKTX
Relative Strength Index (RSI) 49.17 51.17
Support Level $5.69 $1.88
Resistance Level $6.69 $3.65
Average True Range (ATR) 0.54 0.27
MACD 0.03 -0.01
Stochastic Oscillator 40.54 36.51

Price Performance

Historical Comparison
NERV
NKTX

About NERV Minerva Neurosciences Inc

Minerva Neurosciences Inc a clinical-stage biopharmaceutical company focused on the development and commercialization of certain proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. Its product candidate, Roluperidone, is in development for the treatment of negative symptoms in patients diagnosed with schizophrenia. Its Clinical-Stage Programs include Roluperidone and Seltorexant. The company's operations are organized into one operating and reportable segment focused on the development and commercialization of proprietary product candidates to treat patients suffering from CNS diseases.

About NKTX Nkarta Inc.

Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK-cell expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.

Share on Social Networks: